ライフサイエンスコーパス: lupus

1 f the gut mucosa to systemic autoimmunity in lupus.

2 nd evaluated its ability to alleviate murine lupus.

3 autoimmune Ab development in mouse models of lupus.

4 therapy is challenging for individuals with lupus.

5 acting as a potential therapeutic target for lupus.

6 -induced changes in the microbiota influence lupus.

7 teri from the gut to systemic organs worsens lupus.

8 ssue inflammation in a model of TLR7-induced lupus.

9 e coyotes co-occurred with grey wolves Canis lupus.

10 ndependent cohorts comprised of 127 inactive lupus, 107 active LN, 67 active non-renal lupus patients

11 ), snow leopard (P. uncia, 38%), wolf (Canis lupus, 77%) and dhole (Cuon alpinus, 95%) from protected

12 In patients with discoid lupus, a distinct signature consisting of elevated immun

13 r regression analyses examining the Systemic Lupus Activity Questionnaire and log-transformed Brief I

14 derma, cystic fibrosis, dermatomyositis, and lupus, all of which represent unmet medical needs.

15 IFN-lambda protein is increased in murine lupus and IFN-lambda receptor (Ifnlr1) deficiency signif

16 is upregulated in spongiotic dermatitis and lupus and is associated with a dense perivascular T cell

17 that diet modifies genetic susceptibility to lupus and shifts intestinal bacterial and fungal communi

18 role of B cell-expressed TLR9 in regulating lupus and suggest therapeutic potential in modulating an

19 correlate with specific clinical features of lupus and with the presence and severity of coronary art

20 own bears (Ursus arctos), gray wolves (Canis lupus), and wolverines (Gulo gulo).

21 10-2015 we identified individuals tested for lupus anticoagulant(LA), anti-cardiolipin (aCL), and ant

22 y was associated with triple positivity (for lupus anticoagulant, anticardiolipin, and anti-beta2GPI

23 Here, we report that the RBP lupus antigen (La) interacts with the 3'-untranslated re

24 clinical manifestations of neuropsychiatric lupus are well recognized, the underlying molecular-cell

25 ishment and kill rates of gray wolves (Canis lupus) are affected by the coexistence with brown bears

26 synovium to gain insight into the nature of lupus arthritis (LA), using osteoarthritis (OA) and rheu

27 cell function in autoimmune diseases such as lupus as well as in cancer immunotherapy through CAR-T c

28 lations enriched in ISGs and/or in monogenic lupus-associated genes classified patients with the high

29 monstrating that loss of SNERV underlies the lupus autoantigen gp70 overproduction that promotes neph

30 xpression with NF-kappaB activation in mouse lupus B cells, shows that RAB7 is an integral component

31 ed to resemble the polygenic nature of human lupus by embodying three key genetic alterations: the Sl

32 Skin diseases such as lupus, cancer, psoriasis, and hyperhidrosis can potentia

33 lly, to efficiently achieve these goals, the lupus community needs to refine existing clinical resear

34 by clinicians, is now challenging the entire lupus community, from geneticists to clinical investigat

35 tionnaire and log-transformed Brief Index of Lupus Damage scores indicated that increasing frequency

36 ced) and genetic (NZB/W_F1 hybrid) models of lupus development.

37 reased IFN expression and improved cutaneous lupus disease activity, with a favorable safety profile.

38 s) to the risk of predation by wolves (Canis lupus) during winter in northern Yellowstone, USA.

39 toid arthritis (98.1%), followed by systemic lupus erythematosus (0.79%), psoriasis (0.79%), and scle

40 toid arthritis, sicca syndrome, and systemic lupus erythematosus (adjusted OR 1.49 [1.34-1.67], 3.47

41 is with Polyangiitis (aHR=0.21), or Systemic Lupus Erythematosus (aHR=0.32).

42 (2020) suggest that the IFN signature in lupus erythematosus (LE) alters expression of epithelial

43 Systemic lupus erythematosus (lupus) is characterized by aberrant

44 rheumatoid arthritis (n = 25,324), systemic lupus erythematosus (n = 3,951), and/or vasculitis (n =

45 ausative agents in neuropsychiatric systemic lupus erythematosus (NPSLE).

46 0.18 +/- 0.07, P = 7.78 x 10-3) and systemic lupus erythematosus (rg = 0.13 +/- 0.05, P = 3.76 x 10-3

47 tes (T1D) (n = 200, HD n = 200), 3) systemic lupus erythematosus (SLE) (n = 200, HD n = 67; neuro-SLE

48 nterferon (IFN) drives pathology in systemic lupus erythematosus (SLE) and can be tracked via IFN-ind

49 oimmune rheumatic diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA),

50 r instance, the autoimmune diseases systemic lupus erythematosus (SLE) and Sjogren's syndrome affect

51 ritis (RA), osteoarthritis (OA), or systemic lupus erythematosus (SLE) and to identify metabolites as

52 Patients with systemic lupus erythematosus (SLE) are at increased risk for adve

53 s in lupus models and patients with systemic lupus erythematosus (SLE) arise as a consequence of defe

54 Systemic lupus erythematosus (SLE) can directly affect various pa

55 Patients with systemic lupus erythematosus (SLE) display a complex blood transc

56 Patients with Systemic lupus erythematosus (SLE) experience various peripheral

57 Systemic lupus erythematosus (SLE) flares elicit progressive orga

58 Patients with systemic lupus erythematosus (SLE) frequently show symptoms of ce

59 nd clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of

60 tes, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) increase susceptibility to des

61 Systemic lupus erythematosus (SLE) is a clinically heterogeneous

62 Systemic lupus erythematosus (SLE) is a complex autoimmune diseas

63 Systemic lupus erythematosus (SLE) is a complex autoimmune diseas

64 Systemic lupus erythematosus (SLE) is a devastating autoimmune di

65 Systemic lupus erythematosus (SLE) is a multi-organ autoimmune di

66 Systemic lupus erythematosus (SLE) is a multisystem, chronic auto

67 Systemic lupus erythematosus (SLE) is a prototypic autoimmune dis

68 Systemic lupus erythematosus (SLE) is an autoimmune disease chara

69 Systemic lupus erythematosus (SLE) is an autoimmune disease chara

70 Systemic lupus erythematosus (SLE) is an autoimmune disease chara

71 Systemic lupus erythematosus (SLE) is an autoimmune disease, char

72 Systemic lupus erythematosus (SLE) is an autoimmune inflammatory

73 Systemic lupus erythematosus (SLE) is characterized by the expans

74 Systemic lupus erythematosus (SLE) is defined by loss of B cell t

75 Systemic lupus erythematosus (SLE) is mediated by a chronic and d

76 Systemic lupus erythematosus (SLE) is mediated by autoreactive an

77 Systemic Lupus Erythematosus (SLE) is the prototype of autoimmune

78 Systemic lupus erythematosus (SLE) is the prototypic systemic aut

79 ), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis.

80 Most systemic lupus erythematosus (SLE) patients are photosensitive an

81 ar of thrombosis), and only 6.8% of systemic lupus erythematosus (SLE) sera.

82 hritis is a common manifestation of systemic lupus erythematosus (SLE) yet understanding of the under

83 tion in autoimmune diseases such as systemic lupus erythematosus (SLE)(1).

84 are disproportionately affected by systemic lupus erythematosus (SLE), a chronic, potentially debili

85 role in autoimmune diseases such as systemic lupus erythematosus (SLE), a condition characterized by

86 IRF5 are associated with a risk of systemic lupus erythematosus (SLE), and mice lacking Irf5 are pro

87 7 is associated with development of systemic lupus erythematosus (SLE), but the underlying mechanisms

88 n human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms

89 with smoking, hyperopia, diabetes, systemic lupus erythematosus (SLE), greater deprivation (Townsend

90 e of autoimmune diseases, including systemic lupus erythematosus (SLE), is an increased prevalence in

91 In systemic lupus erythematosus (SLE), LL37 also triggers IFN-I in p

92 The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians

93 In systemic lupus erythematosus (SLE), these antibodies bind Fc rece

94 the susceptibility and severity of systemic lupus erythematosus (SLE), using renal disease as a prox

95 7 (TLR7)-dependent mouse models of systemic lupus erythematosus (SLE), we dissect dietary effects on

96 utoimmune diseases, with a focus on systemic lupus erythematosus (SLE), with the relevant translation

97 NA) are prevalent and pathogenic in systemic lupus erythematosus (SLE), yet mechanisms of their devel

98 aneous inflammation is recurrent in systemic lupus erythematosus (SLE), yet mechanisms that drive cut

99 oimmunity and organ inflammation in systemic lupus erythematosus (SLE).

100 nses and plays a pathogenic role in systemic lupus erythematosus (SLE).

101 autoimmune diseases, in particular systemic lupus erythematosus (SLE).

102 d CD8 coreceptors and contribute to systemic lupus erythematosus (SLE).

103 promote an autoinflammatory loop in systemic lupus erythematosus (SLE).

104 s implicated in the pathogenesis of systemic lupus erythematosus (SLE).

105 aria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

106 om patients with autoimmune disease systemic lupus erythematosus (SLE).

107 ch as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

108 egulator of disease pathogenesis in systemic lupus erythematosus (SLE).

109 mage in autoimmune diseases such as systemic lupus erythematosus (SLE).

110 as been linked to the triggering of systemic lupus erythematosus (SLE).

111 estations of the autoimmune disease systemic lupus erythematosus (SLE).

112 F) and plasma from 35 patients with systemic lupus erythematosus (SLE; 15 with NPSLE) showed no antib

113 ation (grouped under the rubric of cutaneous lupus erythematosus [CLE]).

114 t can affect the kidneys, including systemic lupus erythematosus and anti-neutrophil cytoplasmic anti

115 r-old woman with recently diagnosed systemic lupus erythematosus and class IV lupus nephritis confirm

116 An increase in clonality in systemic lupus erythematosus and Crohn's disease that was dominat

117 ic inflammatory diseases, including systemic lupus erythematosus and inflammatory bowel disease, and

118 within the kidneys of patients with systemic lupus erythematosus and lupus nephritis (LN).

119 dermatitis (AD) and psoriasis (PSO) but also lupus erythematosus and oral lichen.

120 present new therapeutic targets for systemic lupus erythematosus and other diseases involving basophi

121 y based on studies in patients with systemic lupus erythematosus and other rheumatic conditions, ther

122 h rheumatologic conditions, such as systemic lupus erythematosus and rheumatoid arthritis

123 he polygenic autoimmune diseases of systemic lupus erythematosus and systemic sclerosis.

124 E play a role in the development of systemic lupus erythematosus and thus represent new therapeutic t

125 e implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies,

126 ions to autoimmune diseases such as systemic lupus erythematosus can differ.

127 Systemic lupus erythematosus carries an increased risk of pregnan

128 Systemic lupus erythematosus is an autoimmune disease characteriz

129 Cutaneous lupus erythematosus lesional skin microarray data and RN

130 We show here that active cutaneous lupus erythematosus lesions are highly colonized (~50%)

131 s who care for patients with severe systemic lupus erythematosus or catastrophic antiphospholipid syn

132 icular helper T cells implicated in systemic lupus erythematosus pathogenesis.

133 affects up to 80% of juvenile-onset systemic lupus erythematosus patients (JSLE).

134 inflammatory DC3s were expanded in systemic lupus erythematosus patients and correlated with disease

135 ons that emerge from the B cells of systemic lupus erythematosus patients can be restored by GA stimu

136 Cutaneous lupus erythematosus patients were grouped according to t

137 om human healthy controls and human systemic lupus erythematosus patients, metformin inhibits the tra

138 od mononuclear cells isolated from cutaneous lupus erythematosus patients, whereas QC and HCQ inhibit

139 analysis of disease activity among systemic lupus erythematosus patients.

140 o affect antimalarial responses in cutaneous lupus erythematosus patients.

141 soriasis, rheumatoid arthritis, and systemic lupus erythematosus predispose to atherosclerotic cardio

142 Systemic lupus erythematosus severity correlates with elevated se

143 and cytokine profiles in lesional cutaneous lupus erythematosus skin could affect antimalarial respo

144 s (LN) is a common manifestation of systemic lupus erythematosus that can lead to irreversible renal

145 neuropathy, Sjogren's syndrome, and systemic lupus erythematosus that have been controlled with immun

146 psoriasis to alopecia areata to vitiligo to lupus erythematosus to atopic dermatitis and food allerg

147 Systemic lupus erythematosus was excluded from all patients as a

148 eficiency causes familial monogenic systemic lupus erythematosus with childhood onset and anti-dsDNA

149 h disease activity in patients with systemic lupus erythematosus with plasmablast-associated flares.

150 he involvement of these proteins in systemic lupus erythematosus(12-14).

151 rf21-a gene that is associated with systemic lupus erythematosus(4,5)-interacts with the endolysosoma

152 or giant cell arteritis to 2.82 for systemic lupus erythematosus).

153 MCD compared with Hodgkin lymphoma, systemic lupus erythematosus, and reactive lymph nodes, suggestin

154 nflammatory skin diseases including systemic lupus erythematosus, angioedema, pemphigus, bullous pemp

155 pathology observed in patients with systemic lupus erythematosus, autoreactive Abs secreted by autore

156 lex diseases like Crohn disease and systemic lupus erythematosus, highlighting the value of examining

157 nsion was frequent in patients with systemic lupus erythematosus, in which it correlated to relative

158 as rheumatoid arthritis, diabetes, systemic lupus erythematosus, inflammatory bowel disease, psorias

159 ials are the primary treatment for cutaneous lupus erythematosus, not all patients are equally respon

160 inical autoimmunity and established systemic lupus erythematosus, plasmacytoid dendritic cells are no

161 and autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and systemic s

162 disorder; systemic diseases such as systemic lupus erythematosus, Sjogren syndrome or Behcet disease

163 connective tissue diseases, such as systemic lupus erythematosus, systemic sclerosis, and myositis.

164 ases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, vasculitis or i

165 ons such as Alzheimer's disease and Systemic Lupus Erythematosus.

166 nal vasculitis or inflammation, and systemic lupus erythematosus.

167 and effective for the treatment of systemic lupus erythematosus.

168 isease, spinocerebellar ataxia, and systemic lupus erythematosus.

169 of autoantibodies in patients with systemic lupus erythematosus.

170 (high)IL-17A(high) subpopulation of systemic lupus erythematosus.

171 cal efficacy in off-label trials of Systemic Lupus Erythematosus.

172 seases, including Crohn disease and systemic lupus erythematosus.

173 -host disease, type 1 diabetes, and systemic lupus erythematosus.

174 non-coding regions associated with systemic lupus erythematosus.

175 uman autoimmune diseases resembling systemic lupus erythematosus.

176 ad to what is clinically defined as systemic lupus erythematosus.

177 first targeted therapy approved for systemic lupus erythematous (SLE) in over 50 y.

178 Systemic lupus erythematous (SLE) is a heterogeneous autoimmune d

179 whether NEERV mis-expression contributes to lupus etiology is unclear.

180 is lupus hudsonicus) and domestic dog (Canis lupus familiaris).

181 Extant Canis lupus genetic diversity can be grouped into three phylog

182 e inflammatory pathology of diseases such as lupus, given their release of large amounts of NETs.

183 f nonlesional skin in patients with systemic lupus has also identified key abnormalities that likely

184 e feasibility of this method for wolf (Canis lupus hudsonicus) and domestic dog (Canis lupus familiar

185 metry and census data from grey wolves Canis lupus in the Upper Peninsula of Michigan, USA to relate

186 ed features of autoimmune disease, including lupus, in 80.7% of the 26 EXT1/EXT2-associated MN cases

187 Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for effi

188 ollowed over 8 years strongly suggested that lupus inflammation promotes skin carcinogenesis in DLE.

189 eveloped preferentially within the cutaneous lupus inflammation without scarring in MRL/lpr mice (P <

190 These novel mouse models of human lupus inform the requirements for nephritis and provide

191 reating, and identifying novel therapies for lupus is challenging because of its genetic and phenotyp

192 pproach to caring for pregnant patients with lupus is essential to optimize outcomes.

193 Lupus is more prevalent in African American women and wo

194 Knowledge of the etiology of cutaneous lupus is rapidly evolving.

195 Systemic lupus erythematosus (lupus) is characterized by aberrant activity of the immu

196 Transcriptomics and epigenetic assessment of lupus LDGs, autologous normal-density neutrophils, and h

197 as Aicardi-Goutieres Syndrome (AGS) or other lupus-like autoimmune disorders.

198 ) mimics an endogenous antigen and initiates lupus-like autoimmunity.

199 ss-of-function (LOF) mutations who developed lupus-like autoimmunity.

200 and host protein has the potential to drive lupus-like autoimmunity.

201 f B and T cells, autoantibody production and lupus-like disease in mice.

202 (BCAP) promoted many aspects of TLR7-driven lupus-like disease, including Isg15 and Ifit1 expression

203 nd expanded systemically in pristane-induced lupus-like disease.

204 irm their antigenicity and ability to induce lupus-like symptoms.

205 FcgammaRIIA expression in lupus mice also led to thrombosis in lungs and kidneys.

206 al treatment of MRL/lpr and pristane-induced lupus mice with an inhibitor led to significant reductio

207 t with neutrophils in FcgammaRIIA-expressing lupus mice.

208 es of PLA2R-negative presumed primary MN and lupus MN in a validation cohort.

209 t and activation and in the pristane-induced lupus model in mice that mimics the hallmarks of the hum

210 In the pristane-induced murine lupus model, pharmacological inhibition of SphK1 or its

211 o study whether autoreactive plasma cells in lupus models and patients with systemic lupus erythemato

212 ntibody production and autoimmunity in mouse lupus models.

213 In the pristane-induced lupus mouse model, inhibition of IRAK4 reduced the expre

214 In people with SLE and in the MRL-Fas(lpr) lupus mouse model, macrophages and autoantibodies are ce

215 is similar to that seen in the MRL-Fas(lpr) lupus mouse model.

216 ibroelastosis (n = 1) and cutaneous neonatal lupus (n = 4).

217 Treatment of accelerated and severe lupus nephritis (ASLN) mice with Tris DBA resulted in im

218 1/EXT2 staining was detected in pure class 5 lupus nephritis (eight of 18 patients) and in presumed p

219 Juvenile-onset lupus nephritis (LN) affects up to 80% of juvenile-onset

220 to renal damage and to the heterogeneity of lupus nephritis (LN) are not well understood.

221 Lupus nephritis (LN) is a common manifestation of system

222 Lupus nephritis (LN) is a form of glomerulonephritis tha

223 Lupus nephritis (LN) is a major contributor to morbidity

224 Lupus nephritis (LN) was the most common secondary glome

225 rkers continue to show promise in evaluating lupus nephritis (LN).

226 tients with systemic lupus erythematosus and lupus nephritis (LN).

227 ctivity biomarker that varies over time with lupus nephritis activity and treatment.

228 ion by bone marrow cells severely aggravated lupus nephritis and accelerated death.

229 ry CD163 reflects histologic inflammation in lupus nephritis and is a promising activity biomarker th

230 hanisms promote lupus nephritis, we compared lupus nephritis and systemic illness in MRL-Fas(lpr) mic

231 ploration, as current therapeutics targeting lupus nephritis are limited and, thus, in great demand.

232 ed systemic lupus erythematosus and class IV lupus nephritis confirmed with biopsy and treated with m

233 We measured urine CD163 at lupus nephritis flares in patients from a Mexican cohort

234 to kidney biopsy samples from patients with lupus nephritis has begun to define the phenotypes of bo

235 mmune mechanisms that cause tissue injury in lupus nephritis have been challenging to define.

236 IL-34 and its two receptors increase during lupus nephritis in MRL-Fas(lpr) mice.

237 Lupus nephritis is a potentially fatal autoimmune diseas

238 Lupus nephritis is the most common target-organ manifest

239 significantly higher in patients with active lupus nephritis than in patients with active extrarenal

240 one of the 14 cases of mixed class 5 and 3/4 lupus nephritis was positive for EXT1/EXT2.

241 Clinical distinction between patients with lupus nephritis who have active inflammation or chronic

242 diagnosed with crescentic transformation of lupus nephritis, 1 was diagnosed with anti-GBM nephritis

243 In human lupus nephritis, CDM confirmed that myeloid DCs present

244 ly decreased in SLE patients especially with lupus nephritis, compared to healthy controls.

245 t intrarenal and systemic mechanisms promote lupus nephritis, we compared lupus nephritis and systemi

246 s appear translatable to human patients with lupus nephritis, whose expression of IL-34, cFMS, and PT

247 ing the accelerated and deteriorated type of lupus nephritis.

248 quantified in urine, correlates with active lupus nephritis.

249 autoantibody-induced inflammation, including lupus nephritis.

250 r prognostic factors: young age-of-onset and lupus nephritis.

251 immunosuppressive medications in women with lupus nephritis.

252 acrophages and autoantibodies are central to lupus nephritis.

253 g diabetic nephropathy, IgA nephropathy, and lupus nephritis.

254 ecision aid for immunosuppressive therapy in lupus nephritis.

255 he cFMS and PTPRZ receptors in patients with lupus nephritis.

256 the utility of these biomarkers in tracking lupus nephritis.

257 E), and mice lacking Irf5 are protected from lupus onset and severity, but how IRF5 functions in the

258 Lupus onset initiated major changes to the platelet tran

259 Factors associated with SGA were maternal lupus (OR(adj) 4.36, 95% CI [2.32-8.18]), hypertensive d

260 Compared with the provision of the ACR lupus pamphlet (n = 147), participants randomized to the

261 e its deletion had no effect on the clinical lupus parameters in this preclinical model, inhibitors o

262 mediated ERV control may contribute to human lupus pathogenesis.

263 e likely role of LDGs in specific aspects of lupus pathogenesis.

264 ti-ERV antibody reactivity are implicated in lupus pathogenesis.

265 f NZB/W F1 mice with an inhibitor attenuated lupus pathology by reducing serum antinuclear autoantibo

266 nally profiled the blood transcriptome of 92 lupus patients and 43 healthy women during pregnancy and

267 ve lupus, 107 active LN, 67 active non-renal lupus patients and 74 healthy controls, of three differe

268 Since lupus patients are prone to infections, groups of mice w

269 We report that sera of a subset of lupus patients contain autoantibodies directed at regula

270 Increased ERV expression in lupus patients inversely correlated with three putative

271 e up-regulation of tolerogenic CD1c(+)DCs in lupus patients treated with MSCs.

272 or contributor to morbidity and mortality in lupus patients, but the mechanisms of kidney damage rema

273 ession and S1P levels were observed in human lupus patients.

274 itionally, SphK2 expression was unaltered in lupus patients.

275 Lupus pregnancies with fetal complications carried the h

276 lantation and were mirrored in uncomplicated lupus pregnancies.

277 cations for EE-exposure risk for genetically lupus-prone individuals.

278 xcision circles confirm that DN T cells from lupus-prone mice and patients with SLE undergo clonal pr

279 The up-regulated genes within the kidneys of lupus-prone mice during LN development reflected TLS for

280 fecal IgA -abundance and -nAg reactivity of lupus-prone mice showed a positive correlation with even

281 rotein gp70 and resultant nephritis occur in lupus-prone mice, but whether NEERV mis-expression contr

282 lines and increase pathogenic lymphocytes in lupus-prone mice.

283 gate this clinical observation, we subjected lupus-prone MRL/lpr and control (MRL/n) mice to a skin c

284 checkpoints in immature and naive B cells of lupus-prone MRL/lpr and NZB/W mice, as well as patients

285 F1 crosses of lupus-prone New Zealand Black (NZB) and 129 mice to Sner

286 Renal TLS was characterized in lupus-prone New Zealand black x New Zealand white F1 mic

287 ar helper T cell (Tfh)-like subpopulation in lupus-prone NZBxW mice with our binning approach "patter

288 mummified carcass of an ancient wolf (Canis lupus) pup (specimen YG 648.1) was discovered in thawing

289 natures of inflammation did not normalize in lupus, risk of pregnancy complications was increased.

290 ere we describe that rare coding variants in lupus-risk genes are present in most SLE patients and he

291 ition delays disease onset in diverse murine lupus strains, although responsiveness to BAFF inhibitio

292 IgA antibody produced in the intestine under lupus susceptibility.

293 ith field data for a system of wolves (Canis lupus) that prey on wild boar (Sus scrofa), a wildlife r

294 logeneic MSCs might suppress inflammation in lupus through up-regulating tolerogenic DCs.

295 complexity can be exploited to improve human lupus treatments.

296 of whether an organ-specific approach toward lupus trials and treatment should be the wave of the fut

297 Using the NZB/W F1 model of murine lupus, we show that murine IRF5 becomes hyperactivated b

298 , anti-CD40-induced colitis, and spontaneous lupus, will also be presented.

299 ponses in two patients with life-threatening lupus, with the clinical responses sustained by maintena

300 Wolves (Canis lupus) would be expected to scavenge on subsidies from a